116 related articles for article (PubMed ID: 19400192)
1. Design and synthesis of cyclic arodyn analogues by ring-closing metathesis (RCM) for kappa opioid receptor (KOP) antagonists.
Fang WJ; Kulkarni SS; Murray TF; Aldrich JV
Adv Exp Med Biol; 2009; 611():279-80. PubMed ID: 19400192
[No Abstract] [Full Text] [Related]
2. Design, synthesis, and opioid activity of arodyn analogs cyclized by ring-closing metathesis involving Tyr(allyl).
Fang WJ; Murray TF; Aldrich JV
Bioorg Med Chem; 2018 Mar; 26(6):1157-1161. PubMed ID: 29273415
[TBL] [Abstract][Full Text] [Related]
3. Conformational Constraint between Aromatic Residue Side Chains in the "Message" Sequence of the Peptide Arodyn Using Ring Closing Metathesis Results in a Potent and Selective Kappa Opioid Receptor Antagonist.
Gisemba SA; Ferracane MJ; Murray TF; Aldrich JV
J Med Chem; 2021 Mar; 64(6):3153-3164. PubMed ID: 33688737
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis, and pharmacological activities of dynorphin A analogues cyclized by ring-closing metathesis.
Fang WJ; Cui Y; Murray TF; Aldrich JV
J Med Chem; 2009 Sep; 52(18):5619-25. PubMed ID: 19715279
[TBL] [Abstract][Full Text] [Related]
5. Identification of arodyn, a novel acetylated dynorphin A-(1-11) analogue, as a kappa opioid receptor antagonist.
Bennett MA; Murray TF; Aldrich JV
J Med Chem; 2002 Dec; 45(26):5617-9. PubMed ID: 12477343
[TBL] [Abstract][Full Text] [Related]
6. Deletion of Ac-NMePhe(1) from [NMePhe(1) ]arodyn under acidic conditions, part 2: effects of substitutions on pharmacological activity.
Fang WJ; Bennett MA; Murray TF; Aldrich JV
Biopolymers; 2011; 96(1):103-10. PubMed ID: 20560148
[TBL] [Abstract][Full Text] [Related]
7. Structure-activity relationships of arodyn, a novel acetylated kappa opioid receptor antagonist.
Bennett MA; Murray TF; Aldrich JV
J Pept Res; 2005 Mar; 65(3):322-32. PubMed ID: 15787962
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis, and biological activities of cyclic lactam peptide analogues of dynorphine A(1-11)-NH2.
Lung FD; Collins N; Stropova D; Davis P; Yamamura HI; Porreca F; Hruby VJ
J Med Chem; 1996 Mar; 39(5):1136-41. PubMed ID: 8676350
[TBL] [Abstract][Full Text] [Related]
9. [Nalpha-benzylTyr1,cyclo(D-Asp5,Dap8)]- dynorphin A-(1-11)NH2 cyclized in the "address" domain is a novel kappa-opioid receptor antagonist.
Patkar KA; Yan X; Murray TF; Aldrich JV
J Med Chem; 2005 Jul; 48(14):4500-3. PubMed ID: 15999987
[TBL] [Abstract][Full Text] [Related]
10. [2',6'-Dimethyltyrosine]dynorphin A(1-11)-NH2 analogues lacking an N-terminal amino group: potent and selective kappa opioid antagonists.
Lu Y; Nguyen TM; Weltrowska G; Berezowska I; Lemieux C; Chung NN; Schiller PW
J Med Chem; 2001 Sep; 44(19):3048-53. PubMed ID: 11543672
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and opioid activity of side-chain-to-side-chain cyclic dynorphin A-(1-11) amide analogues cyclized between positions 2 and 5. 1. Substitutions in position 3.
Vig BS; Murray TF; Aldrich JV
J Med Chem; 2004 Jan; 47(2):446-55. PubMed ID: 14711314
[TBL] [Abstract][Full Text] [Related]
12. Deletion of Ac-NMePhe(1) from [NMePhe(1) ]arodyn under acidic conditions, part 1: effects of cleavage conditions and N-terminal functionality.
Fang WJ; Bennett MA; Aldrich JV
Biopolymers; 2011; 96(1):97-102. PubMed ID: 20560149
[TBL] [Abstract][Full Text] [Related]
13. A novel N-terminal cyclic dynorphin A analogue cyclo(N,5)[Trp(3),Trp(4),Glu(5)] dynorphin A-(1-11)NH(2) that lacks the basic N-terminus.
Vig BS; Murray TF; Aldrich JV
J Med Chem; 2003 Apr; 46(8):1279-82. PubMed ID: 12672226
[TBL] [Abstract][Full Text] [Related]
14. The effects of C-terminal modifications on the opioid activity of [N-benzylTyr(1)]dynorphin A-(1-11) analogues.
Patkar KA; Murray TF; Aldrich JV
J Med Chem; 2009 Nov; 52(21):6814-21. PubMed ID: 19807094
[TBL] [Abstract][Full Text] [Related]
15. Optimized Ring Closing Metathesis Reaction Conditions To Suppress Desallyl Side Products in the Solid-Phase Synthesis of Cyclic Peptides Involving Tyrosine(
Gisemba SA; Aldrich JV
J Org Chem; 2020 Feb; 85(3):1407-1415. PubMed ID: 31880448
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and opioid activity of conformationally constrained dynorphin A analogues. 2. Conformational constraint in the "address" sequence.
Arttamangkul S; Ishmael JE; Murray TF; Grandy DK; DeLander GE; Kieffer BL; Aldrich JV
J Med Chem; 1997 Apr; 40(8):1211-8. PubMed ID: 9111295
[TBL] [Abstract][Full Text] [Related]
17. Reinstatement of cocaine place-conditioning prevented by the peptide kappa-opioid receptor antagonist arodyn.
Carey AN; Borozny K; Aldrich JV; McLaughlin JP
Eur J Pharmacol; 2007 Aug; 569(1-2):84-9. PubMed ID: 17568579
[TBL] [Abstract][Full Text] [Related]
18. Effects of the substitution of Phe4 in the opioid peptide [D-Ala8]dynorphin A-(1-11)NH2.
Vig BS; Zheng MQ; Murray TF; Aldrich JV
J Med Chem; 2003 Sep; 46(19):4002-8. PubMed ID: 12954053
[TBL] [Abstract][Full Text] [Related]
19. Rational design of dynorphin A analogues with delta-receptor selectivity and antagonism for delta- and kappa-receptors.
Guerrini R; Capasso A; Marastoni M; Bryant SD; Cooper PS; Lazarus LH; Temussi PA; Salvadori S
Bioorg Med Chem; 1998 Jan; 6(1):57-62. PubMed ID: 9502105
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and opioid activity of conformationally constrained dynorphin A analogues. 1. Conformational constraint in the "message" sequence.
Arttamangkul S; Murray TF; DeLander GE; Aldrich JV
J Med Chem; 1995 Jun; 38(13):2410-7. PubMed ID: 7608905
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
